Grants Search Results

Diffuse midline glioma is a devastating disease with no known curative therapy. New treatments using immunotherapy approaches, like CAR T therapy, show promise; however, tumors often escape detection by hiding their target proteins and suppressing the immune response to therapy. Dr. Pomaville seeks to tackle this problem by manipulating RNA modifications in the tumor and body to improve response to CAR T therapy. She has found that drugs that mediate RNA methylation, the most common modification on protein-coding mRNA, increases protein levels of existing CAR T antigens and can induce cell death. This RNA modification mark also influences how the body's immune system responds to tumors. Dr. Pomaville will test this drug in cell-line and immunocompetent models to assess whether manipulation of RNA methylation leads to improved efficacy of CAR T therapy. Dr. Pomaville and team will develop combination strategies that enhance the response to immunotherapy in patients. This grant was awarded at Children's Hospital of Philadelphia and transferred to Seattle Children's Hospital.

This grant is funded by Allied World, a global provider of insurance and reinsurance solutions.

At SSM Health Cardinal Glennon Children's Hospital, children of all ages receive the highest level of compassionate care, regardless of their family's ability to pay. The skilled professionals at The Costas Center provide multidisciplinary care for a wide variety of cancers, including leukemia and lymphoma, bone and soft tissue cancers, brain and spinal cord tumors and more. Dr. Ferguson and colleagues offer both inpatient and outpatient services in a healing environment designed with children and families in mind. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Kapi'olani Medical Center's unique geographic location allows Dr. Si Lim and colleagues to serve children both within the state of Hawaii, but also other ethnically underrepresented populations as those from the United States Affiliated Pacific Islands. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports the establishment of an AYA Cancer Research and Care Coordination Program to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Louisiana State University Health Sciences Center and Manning Family Children's is committed to improving outcomes during and after cancer treatment. This grant supports Clinical team members to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Through the HSHS Wisconsin Clinical Research Institute, children have access to cancer research trials at a location close to home. This grant supports Clinical Researchers to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The University of California, San Francisco's mission is to bring the newest in cancer therapies to everyone they will serve, regardless of background, language, or ability to pay for treatment. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Physicians at the Vannie Cook Clinic in the Rio Grande Valley now have access to the most advanced trials and latest medications through Children's Oncology Group and other Texas-based clinical trials. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Children's Hospital of The King's Daughters (CHKD) cares for children diagnosed with cancer in southeast Virginia and northeast North Carolina. Clinical trials at CHKD allow for children throughout their great region to access novel agents without traveling far from home. This grant supports the Clinical Research Team to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

El Paso Children's Hospital serve's one of the nation's largest medically underserved pediatric populations, addressing disparities affecting Latino and border-region children. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Children's Hospital of Michigan in Detroit's mission is to make sure that all children have access to the best health care and most up to date therapies, and opportunities to participate in medical research. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports the clinical research team to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Golisano Children's Hospital is committed to providing excellent care to all children, adolescents and young adults who are being treated or have been treated with cancer in their region. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The UIC/Rush/Stroger Medical Center Children's Oncology Group Program offers pediatric patients the opportunity to enroll onto COG clinical trials, offering cutting edge treatment, optimal care, and comprehensive follow-up. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Ewing sarcoma is a deadly cancer that affects children and young adults. Dr. Gao and team know that these cancer cells depend on a special protein, ETV6, to stay alive. Certain natural fats inside the cell can weaken this protein and slow the cancer's growth. Dr. Gao and colleagues will learn exactly how these fats affect the cancer cells and will search for medicines that safely increase these fats to damage the tumor. Dr. Gao's research will open the door to new and gentler treatment options for children with Ewing sarcoma.

This grant is made possible through funding from D-Feet Cancer, The Dalton Fox Foundation and named in memory of Dalton, who is the inspiration for the Foundation that is lovingly led by his parents and sister. Dalton loved to tell good jokes and had a contagious sense of humor that lit up any room he walked into. Even on his worst days, he inspired his community and family with his positive outlook. He loved baseball, swimming, fishing and watching Marvel movies and while his time here was much too short, his memory continues to motivate so many. The Foundation is focused on fueling more research for Ewing sarcoma.

This grant funds a student to complete work in pediatric oncology research for the summer. Medulloblastoma is the most common malignant brain tumor in children, and the Group 3 subtype is especially aggressive because it spreads early and often returns after treatment. Dr. Hu and colleagues will study a gene called SMARCD3, which normally helps guide how young brain cells grow, mature, and move to the right places as the brain develops. Dr. Hu believes Group 3 tumors hijack this normal developmental program to help cancer cells spread, and that lowering SMARCD3 may shift this tumor toward a less aggressive state. By studying SMARCD3 in models of brain development and tumor formation, Dr. Hu and colleagues will test whether targeting this pathway will reduce tumor spread and improve outcomes for children. This work is being completed under the mentorship of Dr. Baoli Hu.

Childhood leukemia happens when certain blood cells grow out of control. Dr. Wang'ondu and colleagues will focus on a protein called IKZF1, a transcription factor that helps young immune cells develop normally. In some children, IKZF1 is altered in a way that disrupts this process and makes leukemia more likely to form. Children whose leukemia has IKZF1 changes often have worse outcomes with current treatments. Dr. Wang'ondu will study how a specific change called IKZF1 N159Y disrupts normal immune cell functions and how Dr. Wang'ondu and team can target it with new types of drugs. Dr. Wang'ondu will work to understand how changes in transcription factors like IKZF1 cause leukemia and will help develop more effective treatments for children affected by these changes.